Human mAb 216 + Vincristine
Phase 1Terminated 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphocytic, Acute
Conditions
Leukemia, Lymphocytic, Acute, Leukemia, Acute Lymphoid Leukemia (ALL)
Trial Timeline
Sep 1, 2004 → Jul 1, 2008
NCT ID
NCT00313053About Human mAb 216 + Vincristine
Human mAb 216 + Vincristine is a phase 1 stage product being developed by Twist Bioscience for Leukemia, Lymphocytic, Acute. The current trial status is terminated. This product is registered under clinical trial identifier NCT00313053. Target conditions include Leukemia, Lymphocytic, Acute, Leukemia, Acute Lymphoid Leukemia (ALL).
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00313053 | Phase 1 | Terminated |
Competing Products
20 competing products in Leukemia, Lymphocytic, Acute